Prospective randomized controlled study of CRRT hemofilters for the treatment of acute kidney injury (AKI)

Prospective randomized controlled study of CRRT hemofilters for the treatment of acute kidney injury (AKI) - Prospective randomized controlled study of CRRT hemofilters for the treatment of acute kidney injury (AKI)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016105

Enrollment

Registered

2015-01-15

Start date

2015-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury (AKI)

Interventions

CRRT with 1.8m2 PMMA hemofilter (HEMOFEEL CH-1.8W) CRRT with 1.0m2 PMMA hemofilter (HEMOFEEL CH-1.0N) CRRT with 1.0m2 Polysulfone hemofilter (EXCELFLO AEF-10)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AKI patients (AKIN criteria stage 1 or more) who required CRRT in ICU

Exclusion criteria

Exclusion criteria: - age less than 18 - pregnant women - chronic hemodialysis patients or patients who received RRT before randomization - end stage cancer patients

Design outcomes

Primary

Measure	Time frame
28-day mortality	—

Secondary

Measure	Time frame
60-day mortality. Changes of SOFA score at 3 and 7 days after CRRT. Changes of plasma IL-6 levels at 1, 3, and 7 days after CRRT. Changes of lactate levels at 1, 3, and 7 days after CRRT. ICU free-days at Day 28. RRT free-days at Day 28. Progression to ESRD requiring maintenance hemodialysis. (subgroup analysis) septic AKI and non-septic AKI. with and without endotoxin removal hemoperfusion therapy.	—

Measure

Time frame

60-day mortality. Changes of SOFA score at 3 and 7 days after CRRT. Changes of plasma IL-6 levels at 1, 3, and 7 days after CRRT. Changes of lactate levels at 1, 3, and 7 days after CRRT. ICU free-days at Day 28. RRT free-days at Day 28. Progression to ESRD requiring maintenance hemodialysis. (subgroup analysis) septic AKI and non-septic AKI. with and without endotoxin removal hemoperfusion therapy.

—

Countries

Japan

Contacts

Public ContactShigeo Negi

Wakayama Medical University Division of Nephrology, Department of Inerenal Medicine

shigeon@wakayama-med.ac.jp073-441-0639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026